Table 1.
Examples of RNAi-based antiviral therapy using viral vectors.
| Indication | Vector/RNAi | Response | Ref |
|---|---|---|---|
| TMUV | Ad5/E and NS5 shRNAs | Inhibition of TMUV in Vero cells | [43] |
| Ad wt | Ad5/E1A/pTP amiRs | Decrease in Ad wt infection | [44] |
| HBV | HD Ad/HBV pri-miRs | Inhibition of HBV replication | [52] |
| HBV | HD Ad MTTR/pri-miRs | Long-term inhibition of HBV replication | [53] |
| Ad5 | scAAV9/pT/E1A amiRs | Inhibition of Ad5 replication in vitro | [44] |
| Ad5 | scAAV9/pT/E1A amiRs | Inhibition of Ad5 replication in hamsters | [44] |
| HBV | AAV7,8,9/HBV shRNA | Reduced HBV titers, mRNA and DNA levels | [54] |
| HBV | AAV7,8,9/HBV shRNA | Prevention of HBV hepatocellular adenoma | [55] |
| HBV | scAAV8/pri-miR-31 | HBV suppression for 32 weeks in mice | [56] |
| HIV | MMLV/tat Ribozyme | Safe delivery in HIV patients in phase I trial | [57] |
| HIV | MMLV/anti-HIV Ribozyme | MMLV-containing vector in HIV patients | [58] |
| HIV | MMLV/anti-HIV Ribozyme | Phase II safety, but no efficacy | [59] |
| HIV | HIV-1/shRNAs | Shutdown of HIV-1 replication | [46] |
| HBV | HIV/siRNA HBV pol, core | Decrease in HBV DNA and RNA levels | [60] |
| HIV | HIV/shRNA combination | Suppression of HIV replication | [61] |
| HIV | HIV/shRNA combination | Persistent expression up to 24 months | [62] |
| HIV | HIV/AgoshRNAs | Protection against CCR5-tropic HIV-1 strains | [63] |
| HIV | HIV/shRNA-miRs | Suppression of HIV-1 replication in mice | [24] |
AAV, adeno-associated virus: Ad, Adenovirus; AgoshRNAs, Argonaute 2-dependent shRNAs; amiRs, artificial miRNA; HBV, hepatitis B virus; HD Ad, helper-dependent adenovirus; HIV, human immunodeficiency virus; MMLV, Moloney murine leukemia virus; MTTR, murine transthyretin promoter; pri-miRs, primary miRNAs; pTP, preterminal protein; scAAV, self-complementary adeno-associated virus; SFV, Semliki Forest virus; shRNA, short hairpin RNA; TMUV, Tembusu virus.